Taysha Gene Therapies Operating Expenses 2020-2024 | TSHA
Taysha Gene Therapies operating expenses from 2020 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Taysha Gene Therapies Annual Operating Expenses
(Millions of US $) |
| 2023 |
$88 |
| 2022 |
$165 |
| 2021 |
$173 |
| 2020 |
$43 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Operating Expenses
(Millions of US $) |
| 2024-06-30 |
$22 |
| 2024-03-31 |
$28 |
| 2023-12-31 |
$20 |
| 2023-09-30 |
$21 |
| 2023-06-30 |
$26 |
| 2023-03-31 |
$21 |
| 2022-12-31 |
$56 |
| 2022-09-30 |
$25 |
| 2022-06-30 |
$33 |
| 2022-03-31 |
$50 |
| 2021-12-31 |
$50 |
| 2021-09-30 |
$51 |
| 2021-06-30 |
$41 |
| 2021-03-31 |
$32 |
| 2020-12-31 |
$18 |
| 2020-09-30 |
$15 |
| 2020-06-30 |
$4 |
| 2020-03-31 |
$6 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.334B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
